China Life eyes biotech in healthcare investment push
The biggest Chinese insurer by assets sees Hong Kong's new listing regime as beneficial as the firm looks to build its private equity exposure to the healthcare sector.
China Life is becoming increasingly bullish on healthcare investments now that Hong Kong’s new listing rules have made it easier for up-and-coming biotechnology firms to list on the stock exchange, according to a senior executive at the biggest mainland insurer.
Sign In to Your Account
Access Exclusive AsianInvestor Content!
Please sign in to your subscription to unlock full access to our premium AI resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial—no registration fees required. Click the link to get started.
Note: This free trial is a one-time offer.
¬ Haymarket Media Limited. All rights reserved.